Catégorie : Recherche

SOM Biotech achève le processus de recrutement de l'étude de phase IIb sur le traitement de la chorée dans la maladie de Huntington

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical […]

Prilenia prévoit de déposer une demande d'autorisation de mise sur le marché dans l'UE pour la pridopidine dans la maladie de Huntington

Prilenia announced today that they plan to submit a Marketing Authorization Application in the EU for the use of Pridopidine in the treatment of Huntington’s Disease. According to Dr. Michael […]

Une avancée qui représente un nouvel espoir pour les patients atteints de la maladie de Huntington

Scientists from the Weizmann Institute in Israel have published the results of an animal study which holds tremendous promise for the treatment of Huntington’s Disease.  They have discovered that two […]

uniQure annonce une mise à jour des essais cliniques de phase I/II de la thérapie génique AMT-130 pour le traitement de la maladie de Huntington

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean […]

PTC Therapeutics communique des résultats intermédiaires positifs de l'essai clinique PIVOT-HD chez des patients atteints de la maladie de Huntington

June 21, 2023 PDF Version – Dose-dependent lowering of blood Huntingtin (HTT) protein levels at 12 weeks –– Favorable tolerability profile with no treatment-related serious adverse events or NfL spikes –  – Conference […]

uniQure annonce une mise à jour de l'essai clinique américain de phase I/II de la thérapie génique AMT-130 pour le traitement de la maladie de Huntington

~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural history […]

PRILENIA ANNONCE LES RESULTATS DE L'ETUDE PROOF-HD : DES RÉSULTATS PROMETTEURS, MAIS MITIGÉS !

Today, April 25th, Prilenia announced results from the PROOF-HD clinical trial for Huntington’s Disease. Some of the participants showed significant benefits from the Pridopidine drug, while others did not benefit at all.  This […]

Prilenia obtient la dernière visite d'un patient dans l'étude clinique de phase 3 PROOF-HD pour la maladie de Huntington

PROOF-HD is the only late-stage study in Huntington’s disease targeting clinical progression; topline results expected in early Q2 2023 NAARDEN, Netherlands and WALTHAM, Mass., 28 March 2023 – Prilenia Therapeutics B.V., a […]

Roche/Genentech fait le point sur l'étude GENERATION HD2

Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, […]

Novartis met fin à l'étude VIBRANT-HD

Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news […]